Xeltis appoints Shawn Gage as Vice President of US Clinical Affairs
- Brings extensive experience in design, development, and implementation of US medtech clinical trial strategy for hemodialysis and vascular access
- Follows expansion of Xeltis’ clinical presence in the US after recent IDE approval for aXessTM US pivotal trial
EINDHOVEN, The Netherlands, 23 July 2024 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces that it has appointed Shawn Gage as its new Vice President of US Clinical Affairs.
